Olympus reviewed the following literature titled "effect of ursodeoxycholic acid after self-expandable metal stent placement in malignant distal biliary obstruction: a propensity score¿matched cohort analysis".This multicenter retrospective study was to evaluate the efficacy of ursodeoxycholic acid (udca) in patients with self-expandable metallic stent (sems) for malignant distal biliary obstruction (mdbo) using a propensity score¿matched (psm) cohort analysis.A total of 354 patients were included (294 patients did not receive udca and 60 patients did receive udca).In the psm cohort, the sems occlusion rates in the control and udca groups were 5.5% and 18.2% at 3 months (p =.0732), 9.1% and 36.4% at 6 months (p =.0030), 14.5% and 40.0% at 12 months (p =.0049), and 18.2% and 41.8% after the complete period (p =.0119).Based on the univariate anal ysis results, udca administration (p z.0429) and 8-cm long sems (p =.13) were further assessed by multivariate analysis.In conclusion, administering udca after sems placement in patients with mdbo did not show efficacy for prolonging trbo.Patients receiving udca for more than a month might be at increased risk for sludge occlusion.Type of adverse events/number of patients [control group] (pancreatitis - 6 patients) mild - 4 patients, moderate - 2 patients, cholecystitis - 6 patients.[udca group] (pancreatitis - 2 patients) mild - 1 patient, moderate - 1 patient, cholecystitis - 5 patients, liver abscess - 1 patient.This literature article requires 3 reports.The related patient identifiers are as follows: (b)(4) / tjf-200, (b)(4) / jf-240, (b)(4) / tjf-260v.This medwatch report is for patient identifier (b)(6).There is no report of any olympus device malfunction in any procedure described in this study.
|
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation and correction to the initial with information inadvertently left out.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse events cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.Olympus will continue to monitor field performance for this device.
|